Japanese Pharmas Agree To Lower NHI Prices When Generic Uptake Is Slow

TOKYO - Manufacturers would take "certain degrees of action" to lower national health insurance listed prices if generic penetration failed to reach a certain level in the same composite group during a drug's patented period, according to an industry proposal during the latest Chuikyo pharmaceutical price expert subcommittee meeting March 18